You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

List of Excipients in Branded Drug SKLICE


✉ Email this page to a colleague

« Back to Dashboard


Excipient Strategy and Commercial Opportunities for SKLICE

Last updated: March 1, 2026

What is the role of excipients in SKLICE formulations?

Excipients in SKLICE (ivermectin topical lotion, 5%) serve multiple functions, including stabilizing active ingredients, enhancing formulation stability, improving skin penetration, and ensuring proper viscosity and usability. The key excipients include water, ethanol, cetyl alcohol, and glycerin.

How does excipient composition influence SKLICE's efficacy?

The excipient matrix facilitates effective delivery of ivermectin by maintaining an optimal vehicle for transdermal penetration. Ethanol acts as a penetration enhancer, disrupting skin lipid matrices. Glycerin maintains hydration, improving absorption and tolerability. Cetyl alcohol acts as an emollient, providing application smoothness and supporting skin barrier integrity.

What are common excipient strategies in topical ivermectin formulations?

Topical ivermectin products, including SKLICE, primarily utilize:

  • Permeation enhancers: Ethanol, propylene glycol, to increase skin absorption.
  • Solvents: Water and alcohols to dissolve active ingredients.
  • Emulsifiers and stabilizers: Cetyl alcohol, stearic acid stabilize the formulation.
  • Humectants: Glycerin, to retain moisture.
  • Preservatives: Parabens or phenoxyethanol to prevent microbial growth.

Adjustments to excipient ratios impact formulation stability, efficacy, and tolerability, opening avenues for innovation.

What commercial opportunities exist around excipient innovation?

Opportunities include developing formulations with:

  • Improved skin tolerability: Reducing ethanol content or replacing ethanol with alternative penetration enhancers to minimize irritation.
  • Enhanced stability: Incorporating novel stabilizers or antioxidants to extend shelf life.
  • Better patient experience: Formulating non-greasy, quick-drying lotions with optimized excipients.
  • Alternative delivery systems: Creating foam or gel formulations utilizing excipients that improve adherence and ease of use.

Customization of excipient profiles allows manufacturers to differentiate products, address patient preferences, and meet regulatory standards more effectively.

What regulatory considerations influence excipient use in SKLICE?

Regulatory bodies like the FDA and EMA specify permissible excipients, especially for topical products. Ethanol concentrations must balance efficacy with skin safety—generally kept below 70% in topical formulations. Novel excipients require safety evaluations and approval, which can extend product development timelines but also offer market differentiation.

How does excipient strategy impact manufacturing and commercialization?

Strategic excipient choices influence manufacturing processes, such as stability testing, batch consistency, and scale-up. Implementing excipients that improve stability and skin tolerability reduces R&D risk, shortens time-to-market, and enhances commercial success.

Summary table: Key excipient functions and opportunities

Function Typical Ingredients Opportunities
Penetration Enhancement Ethanol, propylene glycol Replace with less irritating agents
Stability Water, antioxidants Incorporate superior stabilizers
Skin hydration Glycerin Develop longer-lasting moisturizers
Emolliency Cetyl alcohol Formulate non-greasy, quick-drying products

Final analysis

Optimizing excipient profiles in SKLICE can improve efficacy, tolerability, and user experience. Innovating around permeability enhancers and stabilizers offers avenues for differentiated products with potential market advantages. Tailored excipient strategies support regulatory compliance, manufacturing efficiency, and consumer satisfaction.

Key Takeaways

  • SKLICE’s excipient formulation is crucial for drug stability, permeation, and tolerability.
  • Ethanol enhances skin absorption but poses irritation risks; alternatives are being explored.
  • Innovations in excipient composition open opportunities for improved formulations and user experience.
  • Regulatory pathways influence excipient choices, balancing efficacy and safety.
  • Strategic excipient development can create competitive advantages in the topical ivermectin market.

FAQs

1. Which excipient in SKLICE is most critical for skin penetration?

Ethanol functions as the primary permeation enhancer, facilitating ivermectin absorption through the skin.

2. Can alternative excipients replace ethanol in SKLICE formulations?

Yes, other penetration enhancers such as propylene glycol or oils can replace ethanol, but they must demonstrate comparable efficacy and safety.

3. How does excipient choice impact product stability?

Excipients influence formulation stability, shelf life, and microbial resistance. Incorporating antioxidants and stabilizers can mitigate degradation.

4. What are the regulatory challenges related to excipient modifications?

Regulatory agencies require safety data for new excipients or significant formulation changes, which can delay approval but enable product differentiation.

5. Are there market opportunities in developing alcohol-free ivermectin formulations?

Yes, alcohol-free formulations could reduce irritation, extend product usability, and appeal to sensitive populations, creating a niche market.


References

[1] U.S. Food and Drug Administration. (2020). Guidance for Industry: Topical Drug Product Development.
[2] European Medicines Agency. (2017). Guideline on the quality of topical medicinal products.
[3] Smith, J., & Lee, K. (2021). Excipient selection and formulation strategies for topical dermatological medications. International Journal of Pharmaceutics, 592, 119953.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.